Cytox, a University of Birmingham spin out, has relaunched with a custom-built laboratory, a new management team, and £3.5m ($5.5m) from new and existing backers. The UK-based biomedical firm went into administration 18 months ago. However, Cytox has now returned following new investments from fund manager SPARK Impact, life science fund Esperante, seed investor Wren Capital, and the University of Birmingham. Biotech investor Jim Mellon also invested. Cytox has advanced a method of testing for early-stage Alzheimer’s, which was originally developed by Cytox’s science director Dr Zsuzsanna Nagy at the University of Birmingham. In addition to Dr Nagy’s Birmingham lab, the firm has opened a new HQ near Oxford and a research facility near the University of Manchester. Cytox chairman David Evans said: “I am pleased to announce that we have exceeded our expectations for the first round of funding for Cytox at such an exciting juncture. This investment round is expected to exceed £3.5m with around 85 per cent coming from new backers. They are as excited as we are by Cytox’s proposition at a time when an early biomarker for Alzheimer’s is so keenly needed.” He added: “We will now push forward with our plans to complete the remaining steps in assay development, deliver near-term revenue opportunities and conduct prospective clinical studies.”
Cytox back from the brink with $5.5m
Feb 8, 2013 •
LEADERSHIP SOCIETY
Informing, connecting, and transforming the global corporate venture capital ecosystem.The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
More featured content
Halo has researchers on speed dial for corporates
Halo has researchers on speed dial for corporates
How does a corporate find the right university researcher or startup when it's trying to solve a critical problem? Halo has the answer.
How Basel supercharged its spinout rate
How Basel supercharged its spinout rate
Basel has quietly built a life sciences ecosystem that’s becoming hard to ignore.
Crumbling system, fragile lives: can spinouts help in the senior care crisis?
Crumbling system, fragile lives: can spinouts help in the senior care crisis?
From a chest-worn device to help with Parkinson's symptoms to stress measuring socks — here are the spinouts providing support for senior citizens.
Events
Webinar: Innovate to heal - What does the hospital of the future look like?
Apr 10, 2024
Online
Online
Events
GCV Institute: Landing the Value of Corporate Venturing
May 6 -
May 9, 2024
Online
May 9, 2024
Online
Events
GCV Institute: CVC Investment Programs
May 21 -
May 22, 2024
Online
May 22, 2024
Online
Events
GCV Symposium 2024
Jun 24 -
Jun 26, 2024
London (UK)
Jun 26, 2024
London (UK)
Events
Corporate Venture in Brasil 2024 – International Delegation to Brazil
Oct 28 -
Oct 30, 2024
São Paulo (Brazil)
Oct 30, 2024
São Paulo (Brazil)
Top News
test reg